Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.43
+0.16 (3.04%)
At close: Mar 9, 2026, 4:00 PM EDT
5.43
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,960,085
Market Cap
1.34B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Monte Rosa Therapeutics | 147 |
| MoonLake Immunotherapeutics | 130 |
| Zenas BioPharma | 130 |
| Olema Pharmaceuticals | 122 |
| Taysha Gene Therapies | 73 |
| AtaiBeckley | 54 |
SVRA News
- 3 days ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 5 days ago - Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
- 17 days ago - Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 24 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 4 weeks ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 5 weeks ago - Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
- 7 weeks ago - Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Business Wire